201 related articles for article (PubMed ID: 29453624)
21. Acute splenic sequestration in female children with sickle cell disease in the North of Jordan.
Al-Rimawi HS; Abdul-Qader M; Jallad MF; Amarin ZO
J Trop Pediatr; 2006 Dec; 52(6):416-20. PubMed ID: 16951418
[TBL] [Abstract][Full Text] [Related]
22. Hydroxyurea therapy in beta-thalassaemia intermedia: improvement in haematological parameters due to enhanced beta-globin synthesis.
Zeng YT; Huang SZ; Ren ZR; Lu ZH; Zeng FY; Schechter AN; Rodgers GP
Br J Haematol; 1995 Jul; 90(3):557-63. PubMed ID: 7646994
[TBL] [Abstract][Full Text] [Related]
23. Response to hydroxyurea therapy in beta-thalassemia.
Koren A; Levin C; Dgany O; Kransnov T; Elhasid R; Zalman L; Palmor H; Tamary H
Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
[TBL] [Abstract][Full Text] [Related]
24. Thalassaemia in Sri Lanka: implications for the future health burden of Asian populations. Sri Lanka Thalassaemia Study Group.
de Silva S; Fisher CA; Premawardhena A; Lamabadusuriya SP; Peto TE; Perera G; Old JM; Clegg JB; Olivieri NF; Weatherall DJ
Lancet; 2000 Mar; 355(9206):786-91. PubMed ID: 10711926
[TBL] [Abstract][Full Text] [Related]
25. Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.
Karimi M; Haghpanah S; Farhadi A; Yavarian M
Int J Hematol; 2012 Jan; 95(1):51-6. PubMed ID: 22180324
[TBL] [Abstract][Full Text] [Related]
26. Serum angiogenin level in sickle cell disease and beta thalassemia patients.
Matter RM; Abdelmaksoud AA; Shams MA; Bebawy EK
Pediatr Hematol Oncol; 2014 Feb; 31(1):50-6. PubMed ID: 24483841
[TBL] [Abstract][Full Text] [Related]
27. Nineteen years study of beta-thalassaemia in Slovakia.
Fábryová V; Babusík P; Laluhová-Striezencová Z; Drakulová M; Oslancová M; Macichová M; Sakalová A
Cent Eur J Public Health; 2012 Dec; 20(4):239-43. PubMed ID: 23441384
[TBL] [Abstract][Full Text] [Related]
28. Hydroxyurea therapy in 49 patients with major beta-thalassemia.
Zamani F; Shakeri R; Eslami SM; Razavi SM; Basi A
Arch Iran Med; 2009 May; 12(3):295-7. PubMed ID: 19400608
[TBL] [Abstract][Full Text] [Related]
29. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
Yavarian M; Karimi M; Bakker E; Harteveld CL; Giordano PC
Haematologica; 2004 Oct; 89(10):1172-8. PubMed ID: 15477200
[TBL] [Abstract][Full Text] [Related]
30. Study of alpha hemoglobin stabilizing protein expression in patients with β thalassemia and sickle cell anemia and its impact on clinical severity.
Mahmoud HM; Shoeib AA; Abd El Ghany SM; Reda MM; Ragab IA
Blood Cells Mol Dis; 2015 Dec; 55(4):358-62. PubMed ID: 26460260
[TBL] [Abstract][Full Text] [Related]
31. Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in beta thalassaemia.
Saxon BR; Rees D; Olivieri NF
Br J Haematol; 1998 Jun; 101(3):416-9. PubMed ID: 9633880
[TBL] [Abstract][Full Text] [Related]
32. The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study.
Koc A; Gumruk F; Gurgey A
Pediatr Hematol Oncol; 2003 Sep; 20(6):429-34. PubMed ID: 14631615
[TBL] [Abstract][Full Text] [Related]
33. Clinical and laboratory effects of long-term administration of hydroxyurea to patients with sickle-cell/beta-thalassaemia.
Voskaridou E; Kalotychou V; Loukopoulos D
Br J Haematol; 1995 Mar; 89(3):479-84. PubMed ID: 7537527
[TBL] [Abstract][Full Text] [Related]
34. Association of BCL11A genetic variant (rs11886868) with severity in β-thalassaemia major & sickle cell anaemia.
Dadheech S; Madhulatha D; Jainc S; Joseph J; Jyothy A; Munshi A
Indian J Med Res; 2016 Apr; 143(4):449-54. PubMed ID: 27377501
[TBL] [Abstract][Full Text] [Related]
35. [Effectiveness and acceptance of hydroxyurea in the treatment of severe forms of sickle cell disease: a prospective study of 65 cases].
Mellouli F; Chouaibi S; Dhouib N; Ouederni M; Ben Khaled M; Abbes S; Bejaoui M
Tunis Med; 2013; 91(8-9):544-50. PubMed ID: 24227514
[TBL] [Abstract][Full Text] [Related]
36. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
[TBL] [Abstract][Full Text] [Related]
37. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia.
Bradai M; Pissard S; Abad MT; Dechartres A; Ribeil JA; Landais P; de Montalembert M
Transfusion; 2007 Oct; 47(10):1830-6. PubMed ID: 17880608
[TBL] [Abstract][Full Text] [Related]
38. Hydroxyurea and blood transfusion therapy for Sickle cell disease in South Asia: inconsistent treatment of a neglected disease.
Darshana T; Rees D; Premawardhena A
Orphanet J Rare Dis; 2021 Mar; 16(1):148. PubMed ID: 33757549
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of high performance liquid chromatography (HPLC) pattern and prevalence of beta-thalassaemia trait among sickle cell disease patients in Lagos, Nigeria.
Adeyemo T; Ojewunmi O; Oyetunji A
Pan Afr Med J; 2014; 18():71. PubMed ID: 25400838
[TBL] [Abstract][Full Text] [Related]
40. Successful application of preimplantation genetic diagnosis for beta-thalassaemia and sickle cell anaemia in Italy.
Chamayou S; Alecci C; Ragolia C; Giambona A; Siciliano S; Maggio A; Fichera M; Guglielmino A
Hum Reprod; 2002 May; 17(5):1158-65. PubMed ID: 11980733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
